Pilot, single-centre, open-label, dose-escalation phase I/II study of treprostinil for prevention of ischemia and reperfusion injury in adult orthotopic liver transplant recipients

Trial Profile

Pilot, single-centre, open-label, dose-escalation phase I/II study of treprostinil for prevention of ischemia and reperfusion injury in adult orthotopic liver transplant recipients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Reperfusion injury
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Oct 2017 New trial record
    • 01 Sep 2017 Results published in the Clinical Pharmacology in Drug Development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top